Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus EPROSARTAN MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus EPROSARTAN MESYLATE.
AVALIDE vs EPROSARTAN MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Eprosartan mesylate is an angiotensin II receptor antagonist (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
Oral, 600 mg once daily. May increase to 800 mg once daily if inadequate response.
None Documented
None Documented
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Terminal elimination half-life is about 5–9 hours. Clinical context: supports once-daily dosing for hypertension.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Primarily biliary/fecal (≈90% as unchanged drug); renal elimination accounts for ≈7% (mostly unchanged).
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB